Nivolumab Plus Lenvatinib and Intra-Arterial Locoregional Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Real-World Study.

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Lenvima (lenvatinib) - Eisai, Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/42707588

Bin Huang; Guowen Li; Haixiong Yan; Manping Huang; Muzi Li; Shanzhi Gu; Yang Zhao; Zhengping Xiong

Sep 9, 2026